Leon Giovanny, Carbonel Christophe, Rampuria Aparajit, Rajpoot Ravindra Singh, Joshi Parth, Kanavos Panos
Price Governance and Negotiations, Value and Access and Commercial Development, Novartis Pharma AG, Basel, Switzerland.
Value and Access, Novartis Healthcare Private Limited, Hyderabad, India.
Eur J Health Econ. 2025 Apr;26(3):513-536. doi: 10.1007/s10198-024-01706-x. Epub 2024 Sep 19.
This paper analyses the structure of and variability in taxation and prescription drug distribution policies and quantifies the impact of such policies on the cost of prescription drugs to health systems in 35 countries. Taxes on prescription drugs remain highly prevalent (83% of the sample) although 63% of the sample countries implement a lower than standard VAT rate. Three remuneration types of the wholesale and retail distribution chain have been identified. Wholesale and retail distributors are remunerated on a regressive mark-up basis, which is price-dependent, although fixed fees and fixed percentages, which are non-price dependent, are also highly prevalent. Price component analysis for three groups of products classed as high-, medium- and low-priced suggests that mark-ups plus taxes varied significantly across countries and products, and ranged from 5% to 187% of ex-factory prices. Average margins also vary significantly by countries and products ranging 5-65% of retail prices. The cost of distribution and taxation contributes significantly to prescription drug costs for health systems. Although distribution chain remuneration raises efficiency and overall affordability questions, these need to be considered together with the regulatory framework shaping market structure of the distribution chain, as well as any prevailing horizontal and vertical integration policies. The overall cost of prescription drugs could be reduced immediately by eliminating taxation; this could go some way to alleviate fiscal pressures on health budgets, whilst avoiding resource re-allocation from health to other sectors.
本文分析了税收政策和处方药分销政策的结构及变化情况,并量化了这些政策对35个国家卫生系统中处方药成本的影响。尽管63%的样本国家实施的增值税税率低于标准税率,但对处方药征税的情况仍然非常普遍(占样本的83%)。已确定了批发和零售分销链的三种薪酬类型。批发和零售分销商的薪酬基于递减加价,这取决于价格,不过与价格无关的固定费用和固定百分比也很普遍。对分为高、中、低价三类产品的价格构成分析表明,加价加上税收在不同国家和产品之间差异很大,范围从出厂价格的5%到187%不等。平均利润率在不同国家和产品之间也有很大差异,占零售价格的5%-65%。分销和税收成本对卫生系统的处方药成本有重大影响。尽管分销链薪酬引发了效率和总体可负担性问题,但这些问题需要与塑造分销链市场结构的监管框架以及任何现行的横向和纵向整合政策一起考虑。取消税收可以立即降低处方药的总体成本;这在一定程度上可以缓解卫生预算的财政压力,同时避免资源从卫生领域重新分配到其他部门。